Cargando…
TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening
CRISPR/Cas9 gene editing can inactivate genes in a precise manner. This process involves DNA double-strand breaks (DSB), which may incur a loss of cell fitness. We hypothesize that DSB toxicity may be variable depending on the chromatin environment in the targeted locus. Here, by analyzing isogenic...
Autores principales: | Álvarez, Miguel M., Biayna, Josep, Supek, Fran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352712/ https://www.ncbi.nlm.nih.gov/pubmed/35927263 http://dx.doi.org/10.1038/s41467-022-32285-1 |
Ejemplares similares
-
Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020) -
Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
por: Fito-Lopez, Bruno, et al.
Publicado: (2023) -
CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells
por: Geisinger, Jonathan M, et al.
Publicado: (2020) -
CRISPR/Cas9 and TALE: beyond cut and paste
por: Deng, Liping, et al.
Publicado: (2015) -
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
por: Stolte, Björn, et al.
Publicado: (2018)